Abstract
Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 569-580 |
| Number of pages | 12 |
| Journal | Drug design, development and therapy |
| Volume | 13 |
| DOIs | |
| State | Published - 2019 |
Keywords
- ALK inhibitors
- ALK positive
- Brigatinib
- Non-small cell lung cancer
- TKI
ASJC Scopus subject areas
- Pharmacology
- Pharmaceutical Science
- Drug Discovery
Fingerprint Dive into the research topics of 'Brigatinib for ALK-positive metastatic non-small-cell lung cancer: Design, development and place in therapy'. Together they form a unique fingerprint.
Cite this
Ali, R., Arshad, J., Palacio, S., & Mudad, R. (2019). Brigatinib for ALK-positive metastatic non-small-cell lung cancer: Design, development and place in therapy. Drug design, development and therapy, 13, 569-580. https://doi.org/10.2147/DDDT.S147499